JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ahlquist, R. P.
Right arrow Articles by Levy, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ahlquist, R. P.
Right arrow Articles by Levy, B.
Journal of Pharmacology And Experimental Therapeutics, Vol. 127, Issue 2, 146-149, 1959
Copyright © 1959 by American Society for Pharmacology and Experimental Therapeutics

ADRENERGIC RECEPTIVE MECHANISM OF CANINE ILEUM

Raymond P. Ahlquist 1 and Bernard Levy 1

1 Department of Pharmacology, Medical College of Georgia, Augusta, Georgia

The intestinal inhibitory effect of phenylephrine in the dog is blocked by small doses of the alpha adrenergic blocking agents such as Dibozane.

The intestinal inhibitory effect of isoproterenol is blocked by small doses of its dichloro analog, DCI.

The effect of epinephrinc on the canine ileum is usually not blocked by either kind of blocking agent alone, but is blocked by a combination of the two.

It is, therefore, concluded that in terms of our concept of the adrenergic receptive mechanism the canine ileum has both alpha and beta receptors, and that both receptors subserve relaxation or inhibition.

Submitted on May 11, 1959






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1959 by the American Society for Pharmacology and Experimental Therapeutics.